Global Blood Therapeutics (GBT) has reported a solid first quarter earnings beat, with Q1 GAAP EPS of -$1.20 beating the Street forecast by $0.
Black Friday is past. So is Cyber Monday.
Monday morning Global Blood Therapeutics (GBT) announced the FDA has agreed to GBT’s plan to file for accelerated approval of voxelotor, a unique …
On a day like today, when the entire stock market is under pressure, you must have done something right to see your stock …
Global Blood Therapeutics (NASDAQ:GBT) investors got cold feet today, sending shares tumbling nearly 17%. The reason?
One of Wall Street’s best analysts believes “the first cut” of data evaluating GBT’s sickle cell disease drug is looking pretty good right now.
Pain Therapeutics to try again with REMOXY NDA Investors love biotech stocks for the lottery ticket-like returns they can offer if a company …
These two pharma stocks all have upside of over 100% say top Wall Street analysts.
Today, Global Blood Therapeutics Inc (NASDAQ:GBT) announced design of the pivotal two-part GBT-440 Phase III HOPE trial in evaluating adults and adolescents with …